苯磺酸瑞马唑仑的临床研究进展  

Research progress in Remimazolam Besylate

作　　者：唐韵 杨小博 余愿[1] 舒化青[1] 尚游[1] Tang Yun;Yang Xiaobo;Yu Yuan;Shu Huaqing;Shang You(Department of Critical Care Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院重症医学科,武汉430022

出　　处：《中华重症医学电子杂志》2024年第4期389-393,共5页Chinese Journal Of Critical Care & Intensive Care Medicine(Electronic Edition)

摘　　要：苯磺酸瑞马唑仑是一种新型超短效苯二氮䓬类药物,可在体内被非特异性组织酯酶快速水解为无活性的羧酸代谢物,具有起效快、恢复快、作用时间可预测等特点,其镇静作用能被氟马西尼拮抗,长时间输注不易发生累积,目前已被多个国家批准用于诊疗操作镇静和全身麻醉诱导与维持;初步研究表明其在ICU患者的镇静中具有一定的优势。本文就苯磺酸瑞马唑仑的作用机制、药理作用、临床应用、不良反应及未来的应用前景进行综述,为其进一步开发、研究和应用提供参考。Remimazolam Besylate is a novel,ultra-short-acting Benzodiazepine which rapidly hydrolyzed into an inactive carboxylic acid metabolite by non-specific tissue esterase.It has characteristics of fast onset,quick recovery,and predictable duration of action.Its sedative effect can be antagonized by Flumazenil.Prolonged infusion of Remimazolam besylate is unlikely to result in accumulation.Remimazolam Besylate has been currently approved for procedural sedation,induction and maintenance of general anesthesia in several countries.Preliminary studies have shown certain advantages in critically ill patients sedation.In this study,mechanisms,pharmacokinetics,clinical applications,adverse events and application prospects of Remimazolam besylate are reviewed to provide evidence for its development,research and application.

关 键 词：瑞马唑仑 镇静 重症医学 

分 类 号：R614[医药卫生—麻醉学]